The results of the study were presented by Dr. Yelena Siegel, a senior physician at the Endocrine Institute at Rambam Hospital, who led the study.
At the World Congress of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, held in Scholarship, Spain from April 14-17, an Israeli study on amorphous calcium was presented. This is the largest conference in the field and is expected to be attended by more than 3,200 doctors and researchers from around the world.
The results of the study show that half of the amorphous calcium dose – DENSITY, produced in Israel by the Amorphical company, compared to the classic calcium supplements, in order to stabilize the calcium economy in patients suffering from hypothyroidism. This study joins the findings of a previous clinical study, conducted by Prof. Nahum Weissman at Ichilov Hospital, which proved that amorphous calcium is absorbed by the body 2 to 4.6 times more than crystalline calcium (found in known calcium supplements from the previous generation).
Hypothyroidism, which usually occurs following thyroid removal surgery, results in reduced PTH hormone production and low levels of calcium in the blood. The main symptom of hypothyroidism is a contraction, which results from a low level of calcium in the blood, causing muscle contractions, especially in the face and limbs. In severe cases the contraction may cause subcutaneous bleeding and arrhythmias. The usual treatment is the administration of calcium preparations in extremely high doses and in combination with vitamin D.
The results of the study were presented to the FDA, and now the company is commissioning a multinational and multicenter clinical trial to confirm the results of the initial study.
For the purchase of amorphous calcium density